ANN ARBOR, Mich., Sept. 5, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced the appointment of Daniel (Dan) R. Orlando as chief commercial officer, a newly created position at Aastrom. Most recently, Dan was with Takeda Pharmaceuticals for over 13 years in executive leadership positions in marketing, sales and business development, most recently as vice president, business development for North and South America. Previously, he was with Abbott Laboratories for more than 11 years in progressive sales and marketing roles. During his career, he has helped to establish dozens of pharmaceutical brands including, most significantly, Actos ®. Under Dan's leadership, Actos ® became the top brand in diabetes. Dan holds an M.B.A. in management from Florida Atlantic University and a Bachelor of Science degree from the University of Florida. "Aastrom's experienced team, compelling Phase 2b clinical results and Phase 3 status, combined with overall leadership in the development of cellular therapies, attracted me to the company," said Dan. "Dan has proven success in product and business development in the metabolic field and his experience will positively support the next stage of development for ixmyelocel-T. We are very pleased to have Dan on board as we work to position ixmyelocel-T for FDA review, approval and commercialization," said Tim Mayleben, Aastrom's president and chief executive officer. About Aastrom Biosciences Aastrom Biosciences is the leader in developing patient-specific, expanded multicellular therapies for use in the treatment of patients with severe, chronic cardiovascular diseases. The company's proprietary cell-processing technology enables the manufacture of ixmyelocel-T, a patient-specific multicellular therapy expanded from a patient's own bone marrow and delivered directly to damaged tissues. Aastrom has advanced ixmyelocel-T into late-stage clinical development, including a Phase 3 clinical program to study patients with critical limb ischemia and a planned Phase 2b clinical trial in patients with ischemic dilated cardiomyopathy. For more information, please visit Aastrom's website at www.aastrom.com . For more information on the pivotal REVIVE Phase 3 clinical trial, please visit the trial website at www.revivecli.com . The Aastrom Biosciences, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3663 This document contains forward-looking statements, including, without limitation, statements concerning clinical trial plans and progress, objectives and expectations, clinical activity timing, intended product development, the performance and contribution of certain individuals and expected timing of collecting and analyzing treatment data, all of which involve certain risks and uncertainties. These statements are often, but are not always, made through the use of words or phrases such as "anticipates," "intends," "estimates," "plans," "expects," "we believe," "we intend," and similar words or phrases, or future or conditional verbs such as "will," "would," "should," "potential," "could," "may," or similar expressions. Actual results may differ significantly from the expectations contained in the forward-looking statements. Among the factors that may result in differences are the inherent uncertainties associated with clinical trial and product development activities, regulatory approval requirements, competitive developments, and the availability of resources and the allocation of resources among different potential uses. These and other significant factors are discussed in greater detail in Aastrom's Annual or Transition Report on Form 10-K or 10-K/T, Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. These forward-looking statements reflect management's current views and Aastrom does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this release except as required by law.
CONTACT: Media contact Andrea Coan Berry & Company firstname.lastname@example.org (212) 253-8881 Investor contact Danielle Spangler The Trout Group email@example.com (646) 378-2924